-
Find a Clinical Trial
-
Get Connected
-
Scientific Report
-
Get Involved
-
About MRA
Without doubt, much will be written about 2020 in the years to come - from the news headlines of COVID-19 and the US elections, to melanoma specific achievements such as exciting clinical trials results and our own efforts to fuel a revolution in research. Today, however, we choose to look forward to the near horizon and to share the top five items that has our team excited for the coming year in the fight against melanoma.
Following the initial shock of her melanoma diagnosis and the strain of facing treatments on her own because of COVID-19, Barbara was faced with yet another hurdle. Her arm surgery had left it nearly immobile. Not only was this a problem for her daily functioning, it made it extremely difficult for Barbara to pursue her lifelong passion of art.
Today, Gail has been ‘off’ treatment for over a year. Her scans – first every three months, now relaxed to four, and soon to six months – continue to show no evidence of disease. She is now a staunch proponent of clinical trials, getting a second opinion, and for sticking up for yourself throughout the process. This is Gail's story.
MRA is powering a revolution in melanoma research. A revolution that is not only benefiting patients with melanoma but also impacting the field of oncology at large.
Despite immense progress, there are still too many patients who are not yet benefiting from even the latest advancements. To address this, MRA is investing in research to identify predictive biomarkers, innovative telemedicine models of care, and big data and artificial intelligence to help move the field ahead.
The annual Society for the Immunotherapy for Cancer (SITC) meeting did not disappoint, despite its virtual format, when it came to new clinical advances for melanoma. Researchers presented data from several important clinical trials and highlighted several novel agents that may boost responses to checkpoint immunotherapy.
